RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Inclusion Criteria

• •Diagnosed with AML according to the 2022 WHO diagnostic criteria;
• •Age 60-75 years;
• •Intermediate to high-risk AML according to the ELN criteria, AML with myelodysplasia-related changes (AML-MRC) or therapy-related AML (t-AML), or core-binding factor AML (CBF-AML) with D816 KIT mutation; or newly diagnosed hypercellular leukemia (WBC ≥ 10×10\^9/L);
• •Achieved CR or CR with incomplete hematologic recovery (CRi) after one to two courses of induction chemotherapy;
• •Have a matched related, haploidentical, or mismatched unrelated hematopoietic stem cell donor;
• •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; Creatinine clearance ≥ 60 mL/min (calculated using the Cockcroft-Gault formula);
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal (ULN), and total bilirubin ≤ 2× ULN;
• •Echocardiography (ECHO) showing left ventricular ejection fraction (LVEF) ≥ 50%; Expected survival \> 8 weeks;
• •Voluntarily signed the informed consent form and can understand and comply with the study's requirements.